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of TP53 accumulation in the absence of detected
mutations is associated with poor prognosis
R Abdel-Fattah', C Challen1, TRL Griffiths2, MC Robinson3, DE Neal23 and J Lunec1
'Cancer Research Unit and 2Department of Surgery, The Medical School, University of Newcastle upon Tyne, Framlington Place, Newcastle upon Tyne
NE2 4HH; 3Department of Pathology, Freeman Hospital, Freeman Rd, Newcastle upon Tyne NE7 7DN, UK
Summary We have used microdissection of paraffin-embedded histological sections and polymerase chain reaction (PCR)-based direct
DNA sequencing for 54 transitional cell carcinoma (TCC) of the bladder, to examine critically the association between TP53 nuclear
accumulation determined by immunohistochemistry and the presence of TP53 mutations, and to examine their relationship to tumour stage
and grade, as well as patient survival. There was a significant association between the presence ofTP53-positive nuclei (> 10%) and a higher
histological stage and grade (P = 0.0115, P = 0.0151 respectively; Fisher's exact). A significant association between TP53 gene mutations
and TP53 nuclear reactivity in more than 10% of tumour cell nuclei was also observed (P= 0.0003; Fisher's exact). Mutations were detected
in 18/54 (33%) cases together with the wild-type sequence when analysed from bulk frozen samples, with significant clustering of mutations
in exons 7 and 8. The microdissection method distinguished more clearly between heterozygous and/or homozygous alterations of the TP53
tumour-suppressor gene, and clearly showed frequent accumulation of TP53 in the absence of mutations. When microdissecting
immunonegative regions from the same paraffin sections, three out of ten samples showed the identical mutations detected in the
immunopositive regions. There was a significant association between TP53 immunoreactivity in more than 50% of tumour cell nuclei and
decreased survival among all patients (P = 0.0325; log-rank test). The patients with TP53 mutations showed a trend for a shorter survival
period; however, the association was not statistically significant at the 95% confidence level (P = 0.132; log-rank test). In conclusion, our
observations show that accumulation of TP53 occurs frequently in the absence of mutations, and that such accumulation is nevertheless
associated with poor survival when it occurs in a high proportion (> 50%) of tumour cell nuclei.
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Ten thousand individuals per year in England and Wales develop
bladder cancer and 5800 die as a result of the disease (Office of
Population Census Statistics, 1993). A total of 90% of bladder
tumours are transitional cell carcinoma (TCC), whereas less
common histological types include squamous cell carcinoma,
adenocarcinoma and sarcoma. Molecular genetic and immuno-
pathological analyses ofbladder cancer have identified abnormali-
ties in a number of chromosomes and genes that appear to be
implicated in the development and progression of such tumours.
These include activation of the H-RAS oncogene (Fujita et al,
1987; Burchill et al, 1994; Hong et al, 1996; Vageli et al, 1996),
increased expression of epidermal growth factor receptor (Neal et
al, 1990) and inactivation of the retinoblastoma gene (Lipponen
and Liukkonen, 1995) as well as frequent abnormalities of the
TP53 tumour-suppressor gene.
TP53 is a key gene in carcinogenesis, being involved in cell
cycle control and preservation ofgenomic integrity. It co-ordinates
the cellular response to DNA damage and other cellular stresses by
inducing cell cycle arrest (Livingstone et al, 1992) or apoptosis
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(Lowe et al, 1993; Fujiwara et al, 1994), depending on the severity
ofdamage and cell type. TP53 can bind to specific DNA sequences
and activate the expression of genes containing TP53-dependent
promoter regions (Kern et al, 1991; Zhan et al, 1993). A number of
genes have been identified that can be induced in response to TP53
expression, such asMDM2, WAF], GADD45 andBAX, which have
been shown to control or mediate some of the downstream func-
tions of TP53. Loss of TP53 function, most commonly through
point mutation within one ofthe evolutionarily conserved domains,
occurs in approximately half of most major cancers (Baker et al,
1990; Lane 1992), including bladder tumours (Sidransky et al,
1991; Kusser et al, 1994; Vet et al, 1995; Kawasaki et al, 1996).
Many of the point mutations of the TP53 gene lead to accumu-
lation of a stabilized protein product that is detectable by immuno-
histochemistry (Finlay et al, 1988). Our initial sequencing studies
using bulk tumour DNA extracts indicated that only approxi-
mately 50% ofpositively staining samples show evidence of TP53
mutations when analysed by PCR-based direct DNA sequencing.
Because of tumour heterogeneity and the presence of normal
stromal cells, wild-type TP53 can mask the detection of small
amounts of mutated TP53. It is therefore difficult to conclude
from such studies that accumulation of immunohistochemically
detectable TP53 can occur in the absence of mutations. Thus, the
aim of this study was to examine more critically the direct associ-
ation between TP53 protein overexpression and the presence of
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mutations and to compare the relationship of these observations
to patient survival. This was performed by microdissecting the
immunopositive regions from paraffin-embedded sections for
selective molecular analysis. The results of this were compared
with those obtained from microdissection of the immunonegative
regions from the same histological sections and, in addition, the
results were compared with molecular analysis performed on bulk
frozen tumours from the same patients.
MATERIALS AND METHODS
Tumour samples
A total of54 TCC ofthe bladder were available for study from the
Urology Department of the Freeman Hospital, Newcastle Upon
Tyne, UK. Parts ofthe tumours were snap frozen in liquid nitrogen
for subsequent PCR and sequencing. The remaining parts were
fixed in formalin, paraffin embedded and sectioned for routine
histology, immunohistochemistry, microdissection, PCR and
sequencing. Tumours were graded according to World Health
Organization guidelines (Mostofi, 1973), and staged according to
the TNM classification (UICC, 1978).
Immunohistochemistry
Paraffin-embedded sections (4 gm) were incubated with the DO-7
monoclonal antibody (DO-7; Novocastra) to the TP53 protein at a
1:250 dilution using standard immunohistochemical staining
methods, as described previously (Jaros et al, 1992). Sections of
colorectal carcinoma previously found to show intense nuclear
staining for DO-7 were used as positive controls. Negative
controls for background staining were performed by omitting the
primary antibody in each case.
Grading and assessment of immunostaining
Slides were examined for the extent and intensity of nuclear
staining in areas of tumour and for background staining.
Representative sections of each block were stained with haema-
toxylin and eosin and reviewed by a pathologist (MC Robinson) to
check previous grading. The staining was assessed by scoring
1000 cells in the area ofhighest positivity, assessed independently
by two observers using a light microscope (x400). The extent of
nuclear reactivity was scored as the percentage of positively
staining tumour cell nuclei.
Microdissection and DNA extraction
TP53-positive immunoreactive cells were specifically marked on
the stained 4-,im paraffin-embedded sections. Adjacent unstained
and unheated 18 jm sections were marked on the same TP53-
immunopositive regions. The circumscribed tumour regions were
separated from adjacent tissues by direct scraping ofthe slides using
a sterile needle under the light dissecting microscope. The micro-
dissected tissues were then placed in sterile microfuge PCR tubes.
Previous DNA extraction protocols for paraffin-embedded tissue
have used xylene to dissolve the paraffin wax, and then ethanol to
remove the xylene, followed by rehydration through different
percentages ofalcohol, andusually take more than 2 h. Therefore, in
order to save time, a more rapid method was developed in which the
microdissected sections were directly resuspended in 100-150jl of
digestion buffer (50 mM Tris at pH 8.5, 1 mi EDTA and 0.5%
Tween 20), and heated at 95°C in the thermal cycler for 1 min. The
paraffin wax was then removed from the supernatant using a sterile
needle. Proteinase K was added to the buffer to afinal concentration
of 20 jig ml-', and the samples were incubated overnight at 37°C.
The proteinase K was then heat inactivated at 95°C for 10 min, and
the samples stored frozen at -20°C before aliquots were taken for
direct PCR amplification as required. To compare between TP53-
immunopositive and -immunonegative regions, microdissection of
the immunonegative regions from the same histological sections
was also performed. The samples were also analysed for TP53
mutations using bulk frozen tumours without microdissection. DNA
extraction from frozen tumours was performed as previously
described (Burchill et al, 1994).
PCR amplification and direct sequencing of exons 4-9
of the TP53gene
The method of PCR amplification and direct sequencing of exons
4-9 ofthe TP53 gene from genomic DNA, using the biotin method
forpurification ofa single-stranded template, and the sequences of
the primer pairs used, have previously been described in detail
(Challen et al, 1992; Ellison et al, 1995). All PCR reactions were
carefully controlled to ensure absence of background products
when a DNA sample was notincluded. Plastic tubes, tips and solu-
tions (excluding primers) were pretreated with UV irradiation to
ensure destruction ofany contaminating DNA template.
Statistical analysis
Association between TP53 sequencing and TP53 immunoexpres-
sion were assessed by Fisher's exact test (two tailed). In all tests
P < 0.05 was considered to be statistically significant according
to the usual convention. The Kaplan-Meier method (GraphPad
Prism package) was used to estimate survival probability as a
function of time, and the log-rank test to examine differences in
survival between subgroups (Peto et al, 1977). Multivariate
analysis was performed by the Cox proportional hazards method
using the SPSS statistical software package.
RESULTS
Immunohistochemical analysis
Staining for TP53 was predominantly nuclear (Figure lA). The
extent of positive staining of the tumour nuclei for TP53 varied
considerably. In 12/54 (22%) sections, there was no detectable
immunoreactivity. The number of cases in different staining cate-
gories, based on percentage of tumour nuclei showing positive
immunoreactivity, is shown in Table 1. There was a considerable
heterogeneity in the staining pattern from tumour to tumour.
Whereas most tumours (62%) showed a diffuse intense pattern
of nuclear staining (> 75% positivity) (Figure IB), others (38%)
showed staining of individual cell nuclei or small groups of cells
only. There was a statistically significant association between
diffuse staining and a higher histological stage (P = 0.0006;
Fisher's exact); 23/35 (66%) T2-T4 tumours and 3/19 (16%)
Ta-TI tumours showed the diffuse staining pattern. Twelve
tumours showed no detectable TP53 immunoreactivity, and six
(50%) of these were of muscle-invasive stage T3. There was a
statistically significant association between TP53-positive nuclei
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Figure 1 Immunohistochemical staining with D07 monoclonal antibody. A Intense nuclear staining. B greater than 75% TP53 nuclear reactivity (diffuse
pattern)
(> 10%) and a higher histological stage; 9/19 (47%) tumours with
lower stage (Ta-TI) and 29/35 (83%) tumours with higher stage
(T2-T4) showed TP53 reactivity in more than 10% of tumour cell
nuclei (P = 0.0115; Fisher's exact). There was also a significant
association between TP53-positive nuclei (> 10%) and a higher
histological grade; 10/21 (48%) tumours with lower grade (I and II)
and 27/33 (82%) tumours with grade III showed TP53 reactivity in
more than 10% of tumour cell nuclei (P = 0.0151; Fisher's exact).
Only the percentage of positive cells was taken into account for
statistical analysis, regardless ofany variation in intensity.
Molecular analysis of TP53from bulk frozen samples
Full sequence analysis was carried out for exons 4-9 of the TP53
gene, covering the highly conserved domains. Table 2 shows the
mutations detected in 18/54 samples analysed. The mutations were
predominantly of point missense type. The incidence of TP53
mutations was higher in muscle-invasive tumours [14/35 (40%)]
compared with superficial tumours [4/19 (21%)]; however, the
association was not statistically significant (P = 0.2293; Fisher's
exact). Similarly, the incidence of TP53 mutations was greater in
highergrade (III) tumours [14/33 (42%)] than lowergrade (I and II)
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Table 1 Histological classification of transitional cell carcinoma, TP53 nuclear reactivity using the DO-7 monoclonal antibody and patient follow-up
% TP53 nuclear reactivity Follow-up (months)
Total 0 0-10 10-50 50-75 >75 Median Range
Grade
1 1 0 0 0 0 74 74-74
11 20 5 5 3 3 4 30 2-77
III 33 6 0 3 2 22 19 1-84
Stage
Ta 9 5 2 0 0 2 54 9-75
Ti 10 1 2 3 3 1 23 2-75
T2 6 0 1 2 0 3 75 9-84
T3 22 6 0 1 1 14 16 2-80
T4 7 0 0 1 0 6 9 1-36
T, stage (Ta-Ti, superficial; T2-T4, muscle invasive). G, grade (I, well differentiated; II, moderately differentiated; Ill, undifferentiated).
Table 2 TP53 mutations found in 18/54 transitional cell carcinoma of the bladder analysed by direct DNA sequencing
Patient number Stage Grade Exon Codon Base change Amino acid change
1 Ta II 8 287 GAG-TAG Glu-Stopb
10 Ti III 6 192 CAG-TAG Gln-Stopb
11 Ti II 8 271 GAG-MG Glu-Lys
12 Ti II 5 155 ACC-AGC Thr-Ser
20 T2 III 7 248 CGG-CAG Arg-Gln
21 T2 III 7 234 TAC-TGC Tyr-Cys
22 T2 III 8 285 GAG-TAG Glu-Stopb
30 T3b III 8 282 CGG-TGG Arg-Trp
37 T3b III 6 224 GAG-AAG Glu-Lys
38 T3a III 7 256 ACA-GCA Thr-Ala
42 T3b III 7 248 CGG-TGG Arg-Trp
44 T3b III 7 245 GGC-AGC Gly-Ser
45 T3a III 8 272 GTG-ATG Val-Met
6 213a CGA-CGG Arg-Arg
48 T4a III 8 275 TGT-TAT Arg-Tyr
49 T4b II 7 248 CGG-CTG Arg-Leu
50 T4b III 7 241 TCC-TTC Ser-Phe
51 T4b III 8 277 TGT-TAT Cys-Tyr
53 T4a III 7 235 AAC-AGC Asn-Ser
aPolymorphism. bNonsense mutation.
tumours [4/21 (19%)], but again this difference was not statistically
significant (P = 0.1376; Fisher's exact). Of 18 mutations, 14 (78%)
were transitions and 4/18 (22%) were transversions. Although all
samples with TP53 mutations showed reactivity in more than 30%
oftumour cell nuclei, 17!36 (47%) samples that did not have TP53
mutations in exons 4-9 showed reactivity in more than 30%
of tumour cell nuclei detected by immunohistochemistry, and 12
of these 17 (71%) were of high stage (T2-T4). There was an
extremely significant association between the presence of TP53
mutations and TP53 immunoreactivity in more than 10% oftumour
cell nuclei (P = 0.0003; Fisher's exact), with most of the cases of
mutations [16/18; (89%)] occurring in the strongly staining group
(>75% positive nuclei) (Figure 2).
The TP53 mutations detected were single nucleotide changes in
exons 5, 6, 7 and 8, which were predominantly point missense
mutations resulting in a predicted amino acid substitution (Table
2). No mutations in exons 4 or 9 were found. A striking feature
was that the mutations showed evidence of clustering in exons 7
and 8 ofthe TP53 gene. An overall comparison ofthe incidence of
Table 3 Proportion of TP53 mutations found in TCC of the bladder in exons
4-9 of the TP53 gene compiled from five separate studies
TP53exons 4 5 6 7 8 9
Sidransky et al (1991) ND 2 2 5 2 0
Fujimoto et al (1992) 2 2 0 0 2 1
Esrig et al (1993) ND 6 3 8 15 ND
Spruck lIl et al (1993) ND 7 4 7 19 ND
Vet et al (1994) ND 3 1 1 3 ND
Uchida et al (1995) 2 6 1 1 10 0
Newcastle 0 1 2 8 7 0
Total 4 27 13 30 58 1
Proportion 4% 27% 13% 30% 58% 1%
ND, not done.
mutations reported in the literature, with respect to the distribution
of mutations along the TP53 gene in bladder cancer, is summa-
rized in Table 3 and Figure 3. Three samples (nos 1, 10 and 22)
British Journal ofCancer (1998) 77(12), 2230-2238 0 Cancer Research Campaign 19982234 RAbdel-Fattah etal
100-
3 -0
(5
.)
0
C
E
E
co
LO
a-
80-
60-
40-
20-
0U.
Mutant Wild-type
TP53 molecular status
Figure 2 Scatter plot of percentage nuclear staining for TP53 in mutant
(n = 18) compared with wild-type subgroups (n = 36)
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Figure 3 Distribution of mutations along the TP53 gene in transitional cell
carcinoma of the bladder
A
harboured nonsense mutations in exon 6 (codon 192) and exon 8
(codons 287 and 285), which were still associated with positive
staining by immunohistochemistry with the DO-7 monoclonal
antibody that recognizes an epitope localized to codons 35 to 45
(Table 1). Only one sample (no. 45) harboured multiple sequence
alterations, one of which was a silent heterozygous alteration in
exon 6 at codon 213, involving an A to G nucleotide substitution
(Figure 4A). This polymorphism has been described previously
(Mazars et al, 1992; Kessis et al, 1993; Vet et al, 1994). The other
mutation in the same sample was located in exon 8 at Val-272; a
well-known hot spot for mutation of the TP53 gene and shown in
Figure 5 as an additional sequencing example. Three mutations
were observed at Arg-248 ofexon 7, each involving different base
pair changes, and the mutations in exon 8 were all clustered in the
region between codon 271 and codon 287 (Table 2). All mutations
appeared to be heterozygous from bulk sample analysis.
Molecular analysis of the TP53gene from
microdissected TP53-immunopositive and
-immunonegative regions of paraffin-embedded
sections
A panel of 23 paraffin-embedded sections from the 54 samples
was selected for microdissection. The samples were divided into
two groups: group 1 consisted of 10 samples that had shown p53
mutations when analysed from the bulk frozen tumours; group 2
consisted of ten (T2-T4) muscle-invasive tumours and three
(Ta-TI) superficial tumours that had not shown mutations but
were positive for p53 nuclear reactivity. TP53-immunopositive
regions as well as -immunonegative regions were microdissected
in the first group of samples to test whether immunonegative
regions represented subclones oftumour cells without mutations.
Upon microdissection of TP53-immunopositive regions, all
mutations were confirmed in the first group of samples. However,
the microdissection method also showed there to be an unequiv-
ocal homozygous pattern ofmutated TP53 in two cases (no.45 and
C
A C G T
C213-_
Figure 4 Sequencing gels for sample no. 45. A An apparent heterozygous polymorphism at C213 detected from sequencing frozen tumour without
microdissection. B The same polymorphism in the same sample but in a homozygous pattern, showing evidence of allele loss, detected from sequencing a
microdissected paraffin section. C Wild-type sequence from normal bladder sample
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Figure 5 Sequencing gel for sample no. 45 showing a mutation in exon 8 at
C272 (G:C to A:T)
no. 37). Without microdissection, it was impossible to distinguish
homozygous mutations from heterozygous mutations because of
normal cell contamination or tumour cell population hetero-
geneity. When microdissecting immunonegative regions, three out
of ten showed the identical previously found mutations,
suggesting that immunohistochemistry may give false-negative
results for the detection of mutations in some circumstances. No
new mutations were found on microdissection. The full results of
the microdissection analysis are summarized in Figure 6.
TP53 immunoreactivity, TP53 mutation and survival
The relationship between survival and TPS3 status for 52 patients
is shown in the Kaplan-Meier survival curves (Figure 7). The
maximum patient follow-up time was 84 months and the median
follow-up time was 23 months. There was a significant association
between TP53 immunoreactivity in more than 50% of tumour cell
nuclei and decreased survival among all patients (x2 = 4.571;
P = 0.0325, log-rank test) (Figure 7A). The patients with TP53
mutations showed a trend towards a shorter survival period;
however, this association was not statistically significant when
considered in isolation (X2 = 2.258; P = 0.1329, log-rank test)
(Figure 7B). However, when the group with no evidence of muta-
tions was subdivided into subgroups of high positive staining
(>50% positive nuclei) and low positive staining (>50% positive
nuclei), the mutant group was not distinguishable from the high
positive-staining non-mutant group. Furthermore, there was a
significant trend towards better survival for the low positive-
staining non-mutant subgroup (P = 0.0371; log-rank test for trend;
Figure 7C). In multivariate analysis using a Cox proportional
hazards model, including sex, stage, age, grade, TP53 mutational
status and DO-7 staining, with stepwise conditional removal or
addition of variables, only stage was found to be significantly
related to survival (P = 0.009).
DISCUSSION
TP53 mutation is a common genetic alteration in many human
malignancies. A wide range of mutations stabilize the TP53
protein, and its consequent accumulation is detectable by immuno-
histochemistry. Although initial studies indicated an association
Figure 6 A summary of immunohistochemistry and sequencing results obtained from frozen tumours and microdissection of immunopositive and -negative
regions from paraffin-embedded sections in 54 transitional cell carcinoma of the bladder
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Figure 7 Kaplan-Meier analysis of survival in 52 patients with transitional
cell carcinoma of the bladder. A TP53 nuclear expression in >50% of tumour
nuclei was the most significant variable associated with survival (- - -, TP53
immunoreactivity <50%, n = 23; -, TP53 immunoreactivity >50%, n = 29).
Patients with TP53 nuclear overexpression were twice as likely to die of
bladder cancer than those whose tumours had minimal or no TP53
overexpression (X2 = 4.571, P = 0.0325). B The patients with TP53 mutations
showed a trend towards shorter survival time (--- -), wild-type, n = 34;
mutant, n = 18), but the association was not significant (X2 = 2.258,
P = 0.1329). C A comparison between mutant, - * -, wild type with > 50%
positively staining nuclei (-) and wild type with < 50% positively staining
nuclei (--- -). X2 = 4.345, P= 0.0371
between immunohistochemically detectable levels of protein and
the presence of mutations (Bartek et al, 1990; Rodrigues et al,
1990), this relationship has not previously been critically exam-
ined by microdissection studies.
Fifty-four TCC of the bladder were analysed by immuno-
histochemistry for TP53 nuclear accumulation. Whereas there was
significant association between TP53 immunohistochemistry and
mutation detected from frozen samples (P = 0.0003; Fisher's
exact), a significant proportion of cases showed high frequency of
TP53 immunoreactivity in the absence of detectable mutations
(Figure 2). Of 36 samples, 17 (47%) that did not have TP53 muta-
tions in exons 4-9 showed reactivity in more than 30% of tumour
cell nuclei detected by immunohistochemistry, and 12 of these 17
(71%) were muscle-invasive (T2-T4) tumours. Ifthe proportion of
tumour cells containing TPS3 mutations is relatively low
compared with normal cells or tumour cells containing wild-type
TP53, molecular analysis may not detect the mutations in the
tumour cells. Our previous mixing studies with mutant and wild-
type DNA have shown that detection of mutations by direct
sequencing is lost if the proportion of mutant DNA falls below
25% (Burchill et al, 1994). When 10/12 muscle-invasive tumours,
which had shown no mutations from sequencing bulk frozen
tumours, were examined by microdissection and direct sequencing
of only the immunopositive regions from paraffin-embedded
sections, these microdissected regions still proved to be of normal
wild-type TP53 sequence. Several investigators (Barnes et al,
1992; Sjogren et al, 1996) have reported discrepancies between
TP53 protein expression and mutation status. It is known that a
range of cellular stresses or the action of different combinations of
activated oncogenes or tumour-suppressor gene alterations can
influence wild-type TP53 accumulation (Lane, 1992).
Although most TP53 mutations in diverse types of cancer have
been found in exons 4-9 (Hollstein et al, 1991), it is possible that
mutations exist outside these regions of the gene; however, such
mutations have been described in less than 8% of tumours from
many varied studies (Levine et al, 1994) and could not account for
the absence ofmutations in approximately half ofthe samples with
a high frequency (>50%) of positive nuclear staining for TP53
(Figure 2).
In a separate aspect ofour study we also examined a panel often
tumour sections that were analysed previously by PCR-based
sequencing from frozen tumours and had shown TP53 mutations.
Both TP53-immunopositive and -immunonegative regions from
the ten paraffin sections were microdissected. In all cases muta-
tions were confirmed from microdissecting the immunopositive
regions. However, unlike the prior frozen bulk sample analysis, the
microdissection method gave an unequivocal homozygous pattern
of mutated TP53 in two cases. The sample (no. 45) that had shown
an apparent heterozygous polymorphism at C213, when DNA
extracted from frozen tumour without microdissection was
analysed, revealed the presence ofthe same polymorphism but in a
homozygous pattern on microdissection (Figure 4B). Another
sample (no. 37) that had previously shown evidence of both wild-
type and mutant sequence from bulk sample analysis turned out to
have a homozygous mutation at C224 when analysed by micro-
dissection. This suggests that microdissection is more reliable for
distinguishing between heterozygous and homozygous mutations.
The technique is simple, rapid, highly selective and at little addi-
tional cost improves the accuracy of direct sequencing for the
detection of gene alterations specifically in tumour cells or associ-
ated with altered immunohistochemical staining.
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Microdissection also has the potential to shed light on the
clonal evolution of the tumours and their malignant progression.
Interestingly, the sample (no. 45) that has shown the homozygous
polymorphism at C213 also had an apparent heterozygous mutation
at Val-272 confirmed by microdissection in the same DNA sample
(Figure 5). This suggests that deletion of one TP53 allele occurred
before a subsequent mutation, which is only present in a subpopu-
lation of the tumour cells, or alternatively there could have been a
duplication of chromosome 17 following initial allele loss and
subsequently a mutation occurring in one ofthese alleles. The latter
possibility would be more consistent with the microdissected popu-
lation including only cells staining positively for TP53.
Microdissection of heterogeneously staining sections also
revealed, in a proportion of cases, that mutations can be present
despite absence ofTP53 staining, even though adjacent areas with
the same mutation show positive staining. When immunonegative
regions were microdissected from the ten samples that had shown
TP53 mutations, three out of ten showed the same mutations, indi-
cating that immunohistochemistry may give false-negative results.
Technical artefacts could explain the absence of staining in such
cases. Alternatively these regions may genuinely represent areas
of the tumour in which the mutant form does not accumulate. It is
possible that the presence of mutations alone is not the sole deter-
minant of protein accumulation. This is evident with Li-Fraumeni
patients, who do not show evidence of positive immunohisto-
chemical staining of their normal tissues in which all cells are
heterozygous for TP53 mutations.
Our data support previous findings in bladder cancer that
have shown that TP53 mutations are more prevalent in high-grade
invasive bladder cancer (Fujimoto et al, 1992; Vet et al, 1994;
Kusser et al, 1994). We analysed 54 tumour samples and 18
mutations were detected, 14 of which were grade III invasive
tumours. The increased frequency of TP53 mutations in late-stage
high-grade tumours suggests that TP53 mutations are involved
in disease progression. The detection of TP53 mutations in four
superficial (Ta-TI) low-grade tumours indicates that TP53
aberrations may be an early indicator of subsequent invasive
progression in bladder cancer and suggests that they may be
involved in the evolution ofthe tumour to a more malignant form.
This is consistent with observations showing that loss of TP53
function leads to genetic instability and hence the acceleration of
the progression of the cells along the pathway towards invasive
metastatic disease.
A marked clustering of mutations in exons 7 and 8 was evident,
corresponding to conserved domains IV and V of the TP53 gene,
in keeping with other published studies (Table 3), although not
previously noted in the literature. A total of 15/18 mutations (83%)
were located in exons 7 and 8 (Table 2). This corresponds to a
region of TP53 that is involved in DNA binding (Pavletich et al,
1993). Three samples showed mutations at Arg-248 of exon 7,
which is one of the most frequently altered sites in TP53. Arginine
is coded for by CGN and hence is a site for spontaneous mutations
because of methylation-induced deamination of 5'-methylcyto-
sine, and this is observed in sample 42 (Table 2). In addition, Arg-
248 interacts with the DNA minor groove in the A-T-rich region
of the consensus DNA-binding sequence [PuPuPuC(A/T)-
(T/A)GPyPyPy] (Cho et al, 1994). Thus, Arg-248 performs the
critical job of anchoring TP53 to the DNA minor groove, and
missense mutations at this point within the DNA binding domain
of TP53 correlate with loss of DNA binding capacity, resulting in
loss of TP53 suppressor function.
In addition, among the other frequently mutated residues, two
hot spots stood out: Gly-245 and Arg-282 (Table 2). Arg-282 from
the H2 alpha helix plays a structural role in the loop-sheet-helix
motif, being involved in the packing of the H2 helix against the P
hairpin and the Ll loop (Cho et al, 1994). On the other hand, Gly-
245 plays a critical role in the formation of two hydrogen bonds,
one with the backbone carbonyl of Cys-247 (one of the zinc
ligands), and the other with the guanidinium group of Arg-249
(another hot spot mutation). Thus, these two hot spot residues also
appear to play a critical role in stabilizing the structure of the
DNA-binding surface of TP53 (Cho et al, 1994).
Analysis of the frequency, type and site of TP53 mutations can
give important clues to aetiological factors and assist efforts to
distinguish the tumours associated with a particular carcinogen
exposure. The frequency and type of TP53 gene mutations
detected vary with cancer type, indicative of the involvement of
different aetiological factors and environmental carcinogens and
the role of TP53 in particular tissues. For example, in lung cancer,
G:C to T:A transversions are often observed and such mutations
have been shown to be induced by benzo(a)pyrene and polycyclic
aromatic hydrocarbons, which are implicated as carcinogens in
cigarette smoking (Chiba et al, 1990; Takahashi et al, 1991). In the
present study, 14/18 (78%) mutations were transitions and 4/18
(22%) were transversions. The proportion of transitions was not
significantly different from that expected for spontaneous muta-
tions (Lunec and Mellon, 1994). Even though smoking is impli-
cated as a risk factor in bladder cancer, this is different to the
pattern seen in lung cancer, for which there is an excess of trans-
versions. This is because benz(o) pyrene and polycyclic aromatic
hydrocarbons from cigarette smoke react locally in the lung and do
not get into the circulation in significant quantities because oftheir
lack of aqueous solubility. Alkylating agents such as nitrosamines
are more likely carcinogens in the circulation, which arise through
tobacco smoke inhalation, and these are more likely to be associ-
ated with transitions, as found in our study.
A large body of evidence has indicated that TP53 is not only
important in the development and progression of cancer, but is
also a major determinant of response to chemotherapy and radio-
therapy. Although there was a trend for better survival in the group
with no TP53 mutation (Figure 7B), this did not achieve statistical
significance (P = 0.132; log-rank test). TP53 nuclear accumulation
in more than 50% oftumour cells was the most significant variable
associated with survival when considered alone (P = 0.0325; log-
rank test). Patients with TP53 nuclear accumulation were twice as
likely to die of bladder cancer than patients whose tumours had
minimal or no immunohistochemically detectable accumulation.
This implies that accumulation of wild-type TP53 is associated
with poor prognosis. Of further note, when the group of cases
showing absence of mutations was subdivided into high- (>50%)
and low (<50%)-frequency TP53-staining groups and compared
against the mutant group, a statistically significant trend was
evident. This showed that the group with no detectable mutations
and low-frequency TP53 staining had the best long-term survival
rate, whereas the group with no mutations, but with high-
frequency accumulation of wild-type TP53 did poorly and was
indistinguishable from the mutant group taken as a whole (Figure
7C). This has not been previously noted and raises questions about
the functional status ofthe accumulated TP53 in non-mutant cases,
which should be explored further.
In conclusion, the direct selection of immunopositive cells from
histological sections using microdissection is a more reliable
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approach for obtaining homogeneous tumour cell populations.
Comparing the results from templates prepared using the microdis-
section method with standard DNA analysis of bulk frozen tumour
samples, we conclude that the microdissection method is better for
distinguishing between heterozygous and/or homozygous alterations
of the TP53 gene, and can provide information about the clonal
heterogeneity of tumours. In addition, our observations strongly
suggest that accumulation of immunohistochemically detectable
levels ofTP53 occurs frequently in the absence ofmutations in exons
4-9 of the TP53 gene and that such accumulation of TP53 appears
nevertheless to be associated with poorclinical outcome.
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